(BBIO) – Hot FDA News
-
BridgeBio Pharma Inc. (BBIO) Reports Consistently Positive Results from Phase 3 ATTRibute-CM study of Acoramidis
-
BridgeBio Pharma Inc. (BBIO) Climbs 77% Following Positive Phase 2 Cohort 5 Results of Infigratinib
-
Back to BBIO Stock Lookup